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Abstract Glucosamine-6-phosphate deaminase (EC 3.5.99.6) is
an allosteric enzyme that catalyzes the reversible conversion of
D-glucosamine-6-phosphate into D-fructose-6-phosphate and am-
monium. Here we describe the existence of two mammalian
glucosamine-6-phosphate deaminase enzymes. We present the
crystallographic structure of one of them, the long human glu-
cosamine-6-phosphate deaminase, at 1.75 A* resolution. Crystals
belong to the space group P212121 and present a whole hexamer
in the asymmetric unit. The active-site lid (residues 162^182)
presented signi¢cant structural di¡erences among monomers.
Interestingly the region with the largest di¡erences, when com-
pared with the Escherichia coli homologue, was found to be
close to the active site. These structural di¡erences can be re-
lated to the kinetic and allosteric properties of both mammalian
enzymes.
4 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Glucosamine-6-phosphate deaminase (GlcN6P-deaminase,
EC 3.5.99.6), formerly known as glucosamine-6-phosphate
isomerase (EC 5.3.1.10), catalyzes the reversible conversion
of GlcN6P into D-fructose-6-phosphate (Fru6P) and ammo-
nium. Although the enzyme was initially described in pig kid-
ney [1], it has been currently characterized in a variety of
organisms such as Escherichia coli [2], Candida albicans [3],
Musca domestica [4], Plasmodium falciparum [5], Canis fami-
liaris [6], Bos taurus [7] and Homo sapiens [8,9].
The best-studied GlcN6P-deaminase is that from E. coli and
has been characterized from the structural, catalytic and
mechanistic points of view [10^14]. The functional unit of
this particular enzyme is a hexamer of identical 29 kDa sub-
units [2]. The E. coli GlcN6P-deaminase is a K-type allosteric
enzyme, which is activated by substrate cooperativity and by
the allosteric activator N-acetyl-glucosamine-6-phosphate
(GlcNAc6P) [15]. Crystallographic structures of the ‘T’ and
the ‘R’ conformers allowed us to describe the allosteric tran-
sition of the E. coli GlcN6P-deaminase [13,14] and to propose
a catalytic mechanism [10].
The mammalian GlcN6P-deaminases from C. familiaris [6],
B. taurus [7] and H. sapiens [9] have been puri¢ed and their
catalytic parameters determined. Whereas all of them catalyze
the same reaction using GlcN6P and present allosteric activa-
tion by GlcNAc6P, their catalytic and allosteric properties
show signi¢cant di¡erences, which might constitute a paradox
if only one GlcN6P-deaminase exists for each species. The
kinetics obtained for the enzyme from C. familiaris (isolated
from kidney) is a K-type allosteric system such as its E. coli
homologue [6]. In contrast, the kinetics found for the enzymes
from B. taurus (isolated from kidney) and the recombinant
H. sapiens enzyme expressed in E. coli are both V-type-like
allosteric systems [7,9]. Whereas the enzymes from human
and bovine sources show a molecular mass of 32.5 kDa [9],
the canine enzyme presents a molecular mass of 30.4 kDa
[6].
The physiological function of the GlcN6P-deaminase in
mammals is poorly understood. When cells of the baby-ham-
ster kidney line BHK-21 are exposed to high ammonium con-
centrations, GlcN6P-deaminase activity is induced [16]. Under
these conditions, the GlcN6P synthesizing activity from Fru6P
and ammonium is the sole responsible for ammonium assim-
ilation with the concomitant accumulation of UDP-N-acetyl-
glucosamine [17]. Interestingly, the GlcN6P-deaminase prepa-
ration obtained from cells of this line was composed of two
di¡erent proteins of 29.9 and 32.4 kDa [16]. The amino acid
sequence of the amino terminus of each one of these proteins
was determined, yielding fragments with 70% identity [16] and
suggesting the existence of at least two isoenzymes.
The genes encoding GlcN6P-deaminase from mouse [18],
hamster [19] and human [20] sources have been cloned and
sequenced. All of them encode a protein product of 289 res-
idues with a predicted molecular mass of 33 kDa, similar in
size to that isolated from B. taurus kidney and to one of the
enzymes isolated from BHK-21 cells. In this paper we present
the identi¢cation of a putative second GlcN6P-deaminase
gene encoding a product of 276 residues in the mouse and
human genomes. To o¡er further insight into the structural
basis of the di¡erent regulatory and catalytic properties of
these two isoenzymes, we report the crystallographic structure
of the 289-residue-long human enzyme at 1.75 AI resolution
(PDB ID 1NE7) and a computer model of the novel 276-res-
idue-long human enzyme.
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2. Materials and methods
2.1. Puri¢cation of the human recombinant GlcN6P-deaminase
Recombinant expression of the human GlcN6P-deaminase encoded
by the constitutive GNPI gene cloned in pTZ19R was achieved using
the E. coli IBPC590R strain [21]. Pre-cultures were prepared by in-
oculating a single colony of the recombinant strain in 200 ml of LB
medium plus ampicillin and incubated for 4 h at 30‡C. Six £asks with
1 l of LB medium plus ampicillin were inoculated with 50 ml of the
pre-culture and incubated for 8 h at 30‡C. The cells were concentrated
by centrifugation at 5000 rpm. The pellet was washed three times with
150 mM, KCl and the extract was prepared by sonication in 20 mM
EDTA, 150 mM KCl and 100 mM Tris^HCl pH 7.7 and cleared by
centrifugation. The supernatant was precipitated with ammonium sul-
fate and the 40^55% fraction, containing the GlcN6P-deaminase ac-
tivity, was collected and stored for further analysis. When necessary,
the precipitate was dialyzed overnight against 50 mM Tris^HCl pH
8.2. The enzyme was puri¢ed as described elsewhere [7] and concen-
trated to 10 mg ml31.
2.2. Enzyme crystallization
Many crystals were obtained using vapor di¡usion in sitting drops
at 18‡C. The crystal selected for di¡raction was grown in a drop
containing 10 mg ml31 protein with a well solution of 1.68 M ammo-
nium sulfate, 10 mM N-acetyl-glucosamine-6-phosphate and 0.1 mM
2-deoxy-2-amino-D-glucitol-6-phosphate at pH 7. Crystals grew as
long rods in 3 months, reaching dimensions of up to 0.15U1.5 mm.
2.3. Data collection
A solution with the same components and concentrations of the
reservoir plus 35% w/v of trehalose was used as cryoprotectant. After
soaking during 24 h, crystals were £ash-cooled using annealing tech-
niques [22] and thus a 94.6% complete di¡raction data set (Table 1)
up to 1.75 AI resolution was obtained at the Stanford Synchrotron
Radiation Laboratory, in the Station BL 9-1 with a wavelength of
0.78 AI .
2.4. Data integration, molecular replacement and structure re¢nement
Di¡raction data were integrated using the DENZO program [23]
and scaled using the SCALA program from the CCP4 package [24].
The structure was solved using the molecular replacement method
with the whole hexamer of the E. coli GlcN6P-deaminase (PDB entry
1DEA) as poly-alanine template with 266 residues used as the starting
model. The re¢nement procedure was carried out using the CNS
program [25] and the program O was used for model building [26].
In the model building steps we used 2fo-fc and fo-fc electron-density
maps of the whole asymmetric unit to construct the hexameric par-
ticle. Trials to re¢ne the structure using non-crystallographic symme-
tries did not yield results better than 24% in R-value, thus we pro-
ceeded to determine the hexamer as six individual monomers (Table
1). In the ¢nal steps, 2fo-fc and fo-fc electron-density average maps
were used as well as annealed omit maps with a spherical omitted
region. The omitted region was on the active-site cavity to better build
the transition-state analogue (competitive inhibitor).
2.5. Structural analyses
The structural analysis of the ¢nal model was performed using the
program O and coupled programs (see command LSQ_IMPROVE in
program O) [27]. The electron-density average maps were calculated
using the AVE and IMP programs from the RAVE package [27].
2.6. Genomic searches for GlcN6P-deaminase coding genes
Searches were performed upon the National Centre for Biotechnol-
ogy Information databases GenBank [28] and ESTs (Expressed Se-
quence Tags database) [29]. Additional searches were performed upon
the mouse full-length cDNAs public database from the RIKEN
Mouse Gene Encyclopaedia Project [30]. We used the tBLASTn pro-
gram, which compares a protein query sequence against a nucleotide
sequence database dynamically translated in all possible reading
frames [31]. The initial search, using the GenBank database, was
performed using the human GlcN6P-deaminase amino acid sequence
deduced from the cDNA reported by Nomura and collaborators in
the HUGE Protein Database (KIAA0060 number) [20]. The results of
this search showed signi¢cant alignments with the previously reported
289-residue-long GlcN6P-deaminases from mouse, hamster and hu-
man. Moreover, a di¡erent mouse sequence, only 276 residues long,
was found from two sources, adult male testis and 8-day-old embryo.
This novel sequence was also found in the RIKEN Mouse Gene
Encyclopaedia Project [30]. A search performed upon the human ge-
nome using the short mouse GlcN6P-deaminase sequence as query
allowed the identi¢cation of two di¡erent deduced peptide sequences:
(1) one located in chromosome 5 which corresponded to the previ-
ously reported long human GlcN6P-deaminase and (2) a second short
sequence in chromosome 4. The complete sequence for the short copy
was obtained through inspection of the DNA sequence in that chro-
mosome fragment (giM13628777). Exon^intron boundaries were iden-
ti¢ed using the GENSCAN program [32]. All alignments were per-
formed manually using the SEQLAB program of the GCG [33].
2.7. Modelling of the short human GlcN6P-deaminase
The structural model of the short human GlcN6P-deaminase was
built using the long human GlcN6P-deaminase crystallographic struc-
ture as template. The calculations for energy minimization and mo-
lecular dynamics were performed using the Insight II program from
Molecular Simulations Inc [34] and its modules (Homology, Biopoly-
mer and Discover). The simulation was made with the transition-state
analogue molecule in the active-site cavity and 19 crystallographic
water molecules plus a water coat of 5 AI . We calculated 12 000 min-
imization iterations and 20 000 dynamic iterations of 1 fs at 300 K.
The structural analysis was made using the O program [26].
Table 1
Re¢nement statistics and di¡raction data statistics
Re¢nement statistics Di¡raction data statistics
Final R 0.193(0.223)a Cell parameters 109.87 AI (90‡), 110.89 AI (90‡),
180.88 AI (90‡)
Rfree 0.217(0.245)a
(10% of unique re£ections)
Space group P212121
RMS deviation from ideal values Resolution 1.75 AI
Bond lengths 0.005 AI Unique re£ections 2 09 143
Bond angles 1.4‡ Completeness 94.3(96.8)a
Dihedral angles 23.1‡ Multiplicity 3.8(3.6)a
Improper angles 0.85‡ Rsymb 0.052(0.224)a
Estimated coordinate error Range resolution 1.74^29.48 AI
ESD from Luzzati plot 0.19 AI Asymmetric unit and
biological unit
one hexamer
ESD from SIGMAA 0.13 AI I/sigma 9.9(3.4)a
Water molecules 2 194
aValues in parentheses correspond to the highest resolution bin: 1.75^1.86. The Rfree value was obtained using cross-validation throughout the
method and the test set selection was random.
bRsym =gMIn3GInfM/gIn.
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3. Results
3.1. Sequence search and analyses
Two di¡erent sequences encoding putative GlcN6P-deami-
nases were detected in the human genome as described in
Section 2 (Fig. 1). One of these sequences, which we named
GNP1, is located in chromosome 5 (5q31) [35] and encodes a
product of 289 residues with a predicted molecular mass of
32.6 kDa. This gene is actively transcribed in di¡erent tissues
(Table 2). The deduced product of GNP1 corresponds in size
and sequence to the recombinant human GlcN6P-deaminase
described elsewhere [7,9]. The second sequence, GNP2, is lo-
cated in chromosome 4 (4p13) and encodes a product of 276
residues with a predicted molecular mass of 31.08 kDa. The
functionality of GNP2 was assessed by the identi¢cation of
speci¢c expression sequence tags from normal tissues and
transformed cells (Table 2).
The products of GNP1 and GNP2 share 87% identity and
94.5% similarity throughout their sequences. Both genes are
interrupted by ¢ve introns located at identical positions. Its is
important to notice that the amino terminus of each one of
these products matched with one of those obtained by direct
sequencing of the enzymes puri¢ed from hamster cultured
cells (Fig. 1) [16].
3.2. Crystallographic structure determination and re¢nement of
the human GNP1
Crystals of the recombinant human GNP1 were obtained in
complex with the allosteric activator GlcNAc6P, the compet-
itive inhibitor 2-deoxy-2-amino-D-glucitol-6-phosphate, am-
monia and inorganic sulfate (Table 1). The amount of unique
re£ections resulted enough to process the complete asymmet-
ric unit and to re¢ne individual atomic isotropic B factors.
The three-dimensional structure was determined by molecular
replacement using the structure of the hexamer of the E. coli
GlcN6P-deaminase (PDB entry 1DEA) as initial model and
was re¢ned at 1.75 AI resolution. The ¢nal model has an
R=0.20 and an Rfree = 0.22. The asymmetric unit contains
six monomers (5U274 a.a.+1 U281 a.a.) with one allosteric
activator, one trehalose molecule and one sulfate ion in alter-
Fig. 1. Amino acid sequence alignment of mammalian GlcN6P-deaminases isoenzymes. The complete sequence of the orthologous GNP1 gene
products from human, mouse and hamster sources are shown, together with an incomplete product from bovine, with an overall identity rang-
ing between 95.1 and 97.5%. Newly identi¢ed paralogous copies of GNP1, named GNP2, were found on the human and mouse genomes, with
an identity of 96.8% between them. The ¢rst 20 residues of the amino terminus correspond to the sequence directly obtained from the two iso-
enzymes puri¢ed from the BHK-21 line cell [16]. The pipelines indicate the conserved exon^intron boundaries in human GNP1 and GNP2 tran-
scripts. Conserved catalytic residues are highlighted in bold whereas allosteric-site residues are underlined.
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nate conformation with a competitive inhibitor in each mono-
mer. One additional sulfate ion appeared in the inter-hexame-
ric crystal contacts. The C-terminal end presented an electron
density visible only up to residue Glu274 in ¢ve of the six
monomers in the asymmetric unit. Residues Lys275 to
Gln289 were totally disordered in almost all the monomers,
with the exception of monomer ‘A’ where a longer chain was
visible up to residue 281 (Fig. 2). In this case, residues 278 to
281 showed crystalline contacts with a neighboring hexamer.
No density was detected for residues 282 to 289 in monomer
‘A’.
3.3. High structural similarity of GNP1 with the E. coli
enzyme, with the largest di¡erences at the active-site region
and in the C-terminus
The asymmetric unit of GNP1 contained the biologically
active particle, a hexamer with non-crystallographic 32 sym-
metry. A structural alignment by rigid-body superposition be-
tween the E. coli and the GNP1 hexamers showed an RMSD
of 1.15 AI with 1560 K carbon atoms included in the super-
position (260 K carbon atoms per monomer). The monomer
fold was the same as in the E. coli enzyme [10].
3.4. The C-terminus
Although GNP1 and the E. coli enzymes share the same
fold, GNP1 is longer in sequence and a rigid-body superpo-
sition between the two monomeric structures showed large
di¡erences in the main chain at the C-terminus starting at
residue Leu258. In GNP1 a new structure was present with
a short helix (residues 259 to 266) and an extended loop (res-
idues 267 to 274) (Fig. 2). This extended loop builds an an-
chor of the helical structure (249^266), which supports the
loop 240^249, responsible for the inter-monomeric interac-
tions close to the two-fold axis of the hexameric particle.
This inter-monomeric surface is rather £exible in the E. coli
enzyme and is part of the core supporting the 13‡ rotation
associated with the allosteric transition. The anchor in the
C-terminus of the E. coli enzyme is much more £exible than
the one found in GNP1 and this can be one of the structural
properties generating the di¡erences in allosteric behavior.
3.5. The active site
Many of the di¡erences between GNP1 and the E. coli
deaminases were located in the substrate-binding loops of
the active site, in particular in the active-site lid (residues
162 to 182) and the phosphate-binding loop (residues 41 to
44). The K carbon atoms of these residues were more than 0.8
AI apart when both structures were superimposed
(RMSD=0.43 AI for 213 K carbons closer than 0.8 AI ) (Fig.
3A).
A detailed analysis of the six active-site cavities in the di¡er-
ent monomers of GNP1 showed a sulfate ion and a molecule
of 2-deoxy-2-amino-D-glucitol-6-phosphate (the competitive
inhibitor) in each active site, both molecules in alternate con-
formations. This molecules presented partial occupancy and
shared similar coordinates in the phosphate-binding site. The
rotamers of the catalytic residues were the same in the six
monomers in the asymmetric unit.
The residues in the active site of the GNP1 and E. coli
enzymes are fully conserved, with the remarkable exception
of Ser43 (Gly in E. coli). This side chain is placed in good
geometry to build a hydrogen bond with the phosphate moi-
ety of the inhibitor (or the sulfate ion) in the human enzyme.
Moreover, Ser43 is located in the phosphate-binding loop
(residues 41^44), which is one of the few regions where sig-
ni¢cant di¡erences appeared between geometries (Fig. 3). Res-
idue Ser43 also appears in good geometry to bind Arg172,
which is a substrate ligand, and therefore potentially able to
compete with the substrate for this residue, leading to a con-
formational change of the active-site lid (residues 162^185).
Table 2
Expressed sequence tags for several GNP1 and GNP2 genes
Organism Enzyme Length (aa) Entry type Tissue ID number
Human 1 1^289 Chromosomal ^ giM13643897
Human 1 1^197 EST Hypothalamus giM15494294
Human 1 1^213 EST Testis giM15253870
Human 1 1^224 EST Kidney giM13337909
Human 1 1^199 EST Pancreatic islets giM180468
Human 2 1^276 Chromosomal ^ giM13628777
Human 2 1^205 EST Hypothalamus giM15490182
Human 2 1^140 EST Testis giM13999823
Human 2 1^103 EST Kidney giM5887273
Human 2 154^276 EST Kidney giM13335729
Human 2 1^150 EST Pancreatic islets giM15688350
Human 2 1^168 EST Leiomyosarcoma line cells giM10346591
Human 2 1^166 EST Adenocarcinoma line cells giM12613723
Mouse 1 1^289 cDNA Testis giM5353760
Mouse 1 1^289 cDNA Testis giM6754029
Mouse 2 1^276 cDNA Testis giM12853906
Mouse 2 1^276 cDNA 8-day-old embryo giM12856903
Hamster 1 1^289 cDNA Testis giM1177524
Bovine 1 1^42 Peptide Kidney extraction Lara-Lemus et al. [7]
Bovine 1 1^167 EST Mammary tissues giM9607266
Bovine 1 1^155 EST Mammary tissues giM9602899
Bovine 1 1^163 EST Mammary tissues giM9596706
Bovine 1 57^174 EST Mammary tissues giM6860672
Dog 1 158^289 cDNA Testis giM18818168
Dog 2 208^276 cDNA Heart giM23702059
The GNP1 and GNP2 genes encode three GlcN6P-deaminases enzymes in H. sapiens, M. musculus and C. familiaris. Both genes are actively ex-
pressed in several tissues and in four cases they are co-expressed (hypothalamus, testis, kidney and pancreatic islets).
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The lid presented conformational di¡erences among the
di¡erent monomers in the inhibitor-bound human enzyme
(Fig. 3A), all di¡erent from the catalytic conformation of
the lid found in the E. coli enzyme. We interpreted these
di¡erences as conformational disorder in the active site, which
is a characteristic of GNP1. In the bacterial enzyme, a unique
conformation of the active-site lid is observed when the inhib-
itor occupies this cavity, even when phosphate ions were used
as precipitants at 2^4 M concentration [10]. All the mentioned
conformational di¡erences enlarged the GNP1 active-site cav-
ity (as compared to the E. coli cavity) and changed the general
coordination of the phosphate moiety in the substrate.
It is a very uncommon feature for the largest structural
di¡erences between orthologous enzymes to be located in
the active site, in particular in the substrate-binding amino
acids (Fig. 3A,B).
3.6. The allosteric site
The allosteric site in GNP1 is placed in a cleft between two
monomers as in the E. coli enzyme [10]. Additionally, a new
hydrogen bond between the activator O1 atom and the second
monomer His262 NE2 atom was observed. This interaction,
which is not present in the E. coli enzyme, might be related to
the higher a⁄nity observed in GNP1 for the allosteric activa-
tor [9,11]. His262 is part of the longer C-terminus GNP1 and
is not present in the E. coli enzyme.
3.7. Computer model of the short human GlcN6P-deaminase
The products of GNP1 and GNP2 share an identity of 87%
distributed evenly throughout the length of the alignment
without gaps (Fig. 1). As expected, many of the di¡erences
were located at the surface of the protein. Nevertheless, some
of these mutations appeared in positions close to the active
site. These are Phe88Tyr, Phe173Tyr, and Arg172Lys (¢rst the
amino acid in GNP1 and afterwards the one in GNP2). The
Phe to Tyr substitutions added hydroxyl groups to the side
chains, generating close contacts (2.3 AI distance) with the
phosphate-binding loop (residues 41^44). Additionally, new
hydrogen bonds were built along the main chain of the loop
without changing the hydrophobic interactions at side chains
88 and 173 present in the crystallographic structure of the
long enzyme. Furthermore, both minimization and molecular
dynamics procedures (see Section 2) relocate the phosphate-
binding loop. The relocation approached the loop to the ac-
tive-site cavity without changing the hydrophobic interactions
around the aromatic rings of residues 88 and 173 (Fig. 4).
This rearrangement might be su⁄cient for the stabilization
of the active-site lid and the optimal binding conformation
of the inhibitor.
4. Discussion
Here we present the identi¢cation of two GlcN6P-deami-
nase genes (GNP1 and GNP2) in the completely sequenced
genomes of human and mouse (Fig. 1). Kinetic and structural
studies show that both enzymes share the same fold, both are
hexameric particles in solution, present the same catalytic ac-
tivity with the same substrates, and share the same allosteric
activator [6,7,9]. Moreover, these genes are often expressed in
the same tissues. However, their lengths are di¡erent (276 and
289) as well as some amino acids in the proximity of the
active-site cavity. We found that 15 residues in the C-terminal
region of GNP1 are completely disordered in the crystallo-
graphic structure. The amino acid sequence of this C-terminal
segment is very uncommon, as more than 50% of the residues
are charged. Our search for footprints within this sequence
did not produce any positive result. We cannot assign any
speci¢c function for this segment.
The three-dimensional structure of GNP1 shows di¡erent
conformations for the active-site lid in all the six independent
monomers in the crystal. Interestingly, none of them corre-
sponded to the conformation observed in the E. coli enzyme.
Moreover, in all monomers, the phosphate-binding loop is
displaced 1.0 AI from the position known to generate the cat-
Fig. 2. Stereoscopic image of the human GNP1 C-terminus. The long C-terminus of the human GNP1 monomer A (from residue 259 onwards)
interacts with the rest of the protein by hydrophobic interactions (residues Ile4, Leu6, Trp15, Tyr19, Met259, Leu265 and Val266 in purple) as
well as a series of hydrogen bonds involving main chain and side chain residues (indicated by dashed red lines).
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alytic conformation in the E. coli enzyme. The phosphate
moiety of the substrate is thus in a di¡erent position and
the C1, O1, C2 and N2 atoms, which participate in the iso-
merization reaction, did not present electron density in most
of the monomers. The catalytic reaction region is usually the
most conserved portion of all enzymes. In contrast, the com-
puter model of the human GNP2 presented the phosphate-
binding loop in a conformation similar to that of the E. coli
enzyme.
Two di¡erent allosteric systems (V- and K-type systems)
have been reported in the literature for GlcN6P-deaminases
isolated from bovine and canine kidneys. GNP1 can be iden-
ti¢ed with a V-type allosteric system, which is found in bovine
and recombinant human enzymes [7,9]. We suggest that the
product of the human and mouse GNP2 genes might be iden-
ti¢ed with the K-type allosteric system isolated from canine
kidney [6] given their similarity of molecular weights and dif-
ferences observed in its kinetic behavior with that of the
GNP1 product [7,9]. GNP2 seems to be signi¢cantly similar
to the E. coli GlcN6P-deaminase in its kinetic behavior and in
the active-site structure, and therefore we suggest that it can
be a catabolic enzyme, optimized for reaction rate accelera-
tion. In contrast, GNP1 is related to an unusually high a⁄nity
for ammonia (the B. taurus enzyme presents a Km for ammo-
Fig. 3. Rigid-body superposition of the six monomers of human GNP1. The superposition leads to root mean-square deviations between 0.303
and 0.196 AI . The monomers B and F (chains in red and purple) presented the largest di¡erences in the main chain of the active-site lid (resi-
dues 162^182). A: Conformations of the active-site loops in human and E. coli enzymes. The main chains of monomers A, C, D and E are
not shown for simplicity. The active-site lid of monomer F presents an additional hydrogen bond between the Glu177 side chain and the main
chain oxygen of Arg79 of a neighboring hexamer. The structure of the E. coli GlcN6P-deaminase in complex with the competitive inhibitor
molecule is shown in green whereas the structure of the same enzyme free of active-site ligands is shown in yellow. Another signi¢cant di¡er-
ence between the human GNP1 and the E. coli enzyme is at the phosphate-binding loop at residue Ser43 where there is a distance of around
1 AI between corresponding CK carbons. B: Conformational disorder at the active-site lid found in the human GlcN6P-deaminase-inhibitor
complex. GlcN6P-deaminase chains shown are: A (chain in brown), B (chain in red) and F (chain in purple). The E. coli enzyme is represented
in green. The side chains of Arg172 and Phe173 show conformational disorder in the active-site lid of the human enzyme. The monomer A has
alternate conformations in Ser43 and Arg172. The alternative conformations of Ser43 show di¡erent interactions, one bound to the phosphate
of the inhibitor (or sulfate ion) as well as to Arg 172 and the other bound only to Arg 172. This geometry is not observed in the E. coli en-
zyme.
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nia of 3.7 mM) [7] in contrast to the E. coli enzyme with a Km
of 18 mM. [11]. Moreover, the structural di¡erences observed
around the active site of GNP1 when compared to the E. coli
enzyme might be the result of a structural optimization to-
wards a slightly di¡erent function as, for example, ammonia
binding, since the transition-state analogue of the reaction
binds in a disordered fashion.
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